Maria A V Marzolini
Overview
Explore the profile of Maria A V Marzolini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marzolini M, Kayani I, Carpenter B, Laurence A, McLornan D, Raj K, et al.
Eur J Haematol
. 2024 Dec;
114(3):545-555.
PMID: 39663137
Objectives: Deauville scores (DS) from PET/CT imaging are increasingly being used to direct response-adjusted treatment strategies in lymphoma, including large B cell lymphomas (LBCL). We aimed to investigate the outcome...
2.
Marzolini M, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, et al.
Br J Haematol
. 2024 Nov;
206(3):876-886.
PMID: 39604791
Traditionally, patients with asymptomatic, advanced-stage follicular lymphoma were managed with a watchful-waiting approach until disease progression. The 'Watch and Wait' Phase-3 randomised international trial examined whether rituximab could delay the...
3.
Roddie C, Lekakis L, Marzolini M, Ramakrishnan A, Zhang Y, Hu Y, et al.
Blood
. 2023 Feb;
141(20):2470-2482.
PMID: 36821767
Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1...
4.
Marzolini M, Neill L, OReilly M, Peggs K, Roddie C
EJHaem
. 2022 Jul;
3(1):245-246.
PMID: 35846198
No abstract available.
5.
Mackenzie S, Shafat M, Roddy H, Hyare H, Neill L, Marzolini M, et al.
EJHaem
. 2022 Jul;
2(4):848-853.
PMID: 35845220
Progressive multifocal leukoencephalopathy (PML) is an opportunistic brain infection with few treatment options and poor survival when reversal of the underlying immune dysfunction is not achievable. JC polyomavirus reactivation resulting...
6.
Kuhnl A, Roddie C, Kirkwood A, Tholouli E, Menne T, Patel A, et al.
Br J Haematol
. 2022 Apr;
198(3):492-502.
PMID: 35485402
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide...
7.
Kuhnl A, Roddie C, Kirkwood A, Menne T, Cuadrado M, Marzolini M, et al.
Blood Adv
. 2021 Oct;
6(1):321-326.
PMID: 34700342
No abstract available.
8.
Marzolini M, Mehra V, Thomson K, Tholouli E, Bloor A, Parker A, et al.
Blood Adv
. 2021 Oct;
5(21):4500-4503.
PMID: 34614515
No abstract available.
9.
Roddie C, Dias J, OReilly M, Abbasian M, Cadinanos-Garai A, Vispute K, et al.
J Clin Oncol
. 2021 Aug;
39(30):3352-3363.
PMID: 34464155
Purpose: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-generation CD19-CAR (CAT19-41BB-Z)...
10.
Marzolini M, Wilson A, Sanchez E, Carpenter B, Chakraverty R, Hough R, et al.
Transplant Cell Ther
. 2021 May;
27(8):682.e1-682.e12.
PMID: 33962069
Epstein-Barr virus (EBV) load monitoring after allogeneic hematopoietic stem cell transplantation (HSCT) enables earlier detection of EBV replication and often serves as a trigger for preemptive therapies aimed at reducing...